Royalty Pharma
Through the investors’ lenses
Each of these investors has said in public what they look at before buying. Click a name to see how this company measures up — a tick where it passes one of their tests, a cross where it does not.
Warren Buffett 1/3
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Owner earnings | — | positive | — |
| Return on equity | 7.9% | median 11.7% | ✗ |
| Debt to equity | 0.92x | median 0.79x | ✗ |
| Operating margin | 65.6% | median 15.0% | ✓ |
Passes 1 of 3. To be clear: Warren Buffett has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Terry Smith 2/4
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Return on capital employed | 8.4% | median 10.1% | ✗ |
| Cash conversion | 3.23x | median 1.78x | ✓ |
| Operating margin | 65.6% | median 15.0% | ✓ |
| Debt to equity | 0.92x | median 0.79x | ✗ |
Passes 2 of 4. To be clear: Terry Smith has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Charlie Munger 1/3
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Return on capital employed | 8.4% | median 10.1% | ✗ |
| Return on equity | 7.9% | median 11.7% | ✗ |
| Operating margin | 65.6% | median 15.0% | ✓ |
Passes 1 of 3. To be clear: Charlie Munger has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Chuck Akre 1/4
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Return on equity | 7.9% | median 11.7% | ✗ |
| Debt to equity | 0.92x | median 0.79x | ✗ |
| Cash conversion | 3.23x | median 1.78x | ✓ |
| Return on equity, sustained | 2 of 8 | 8 of 10 above median | ✗ |
Passes 1 of 4. To be clear: Chuck Akre has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Philip Fisher 3/4
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Operating margin | 65.6% | median 15.0% | ✓ |
| Net margin | 32.4% | median 10.2% | ✓ |
| Return on capital employed | 8.4% | median 10.1% | ✗ |
| Operating margin, held or improving | 65.6% | 10-yr median 63.4% | ✓ |
Passes 3 of 4. To be clear: Philip Fisher has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Walter Schloss 1/2
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Current ratio | 2.40x | median 1.25x | ✓ |
| Debt to equity | 0.92x | median 0.79x | ✗ |
Passes 1 of 2. To be clear: Walter Schloss has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Benjamin Graham 1/2
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Current ratio | 2.40x | 2.00x published | ✓ |
| Long-term debt to working capital | 9.61x | 1.00x published | ✗ |
Passes 1 of 2. To be clear: Benjamin Graham has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Joel Greenblatt 0/1
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Return on capital employed | 8.4% | median 10.1% | ✗ |
Passes 0 of 1. To be clear: Joel Greenblatt has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Peter Lynch 1/2
| Measure | RPRX | Checked against | |
|---|---|---|---|
| Debt to equity | 0.92x | median 0.79x | ✗ |
| Net margin | 32.4% | median 10.2% | ✓ |
Passes 1 of 2. To be clear: Peter Lynch has never said anything about Royalty Pharma. These are the company’s own figures put through the tests he described. What he looks at, and why →
Free cash flow is not shown for this company. It cannot be computed from what this company files — the inputs are absent from its XBRL, not zero. The figure marked in the table is operating cash flow instead.
| Basis | Payout | Why |
|---|---|---|
| GAAP earnings | 37.7% | whyThe figure most screeners publish. |
| Operating cash flow | 15.2% | whyBefore capital spending. |
No free cash flow figure is shown. This company does not report the inputs for it in its XBRL filings — capital expenditure, in particular, is often folded into a single investing total rather than tagged on its own. The figure is absent from the filings, not zero, and inventing one from a balance-sheet movement would be a guess dressed as a measurement.
Spread between highest and lowest: 22.5 percentage points. Same filings, different denominators.
Coverage rating 58 / 100 — Tight. ? Peer standing · not rankedDirection 18/30Stability 11/20
Operating cash flow payout, last 6 years
| Fiscal year | Payout |
|---|---|
| 2025-12-31 | 15.2% |
| 2024-12-31 | 13.6% |
| 2023-12-31 | 12.0% |
| 2022-12-31 | 15.5% |
| 2021-12-31 | 14.1% |
| 2020-12-31 | 5.5% |
The arithmetic
- GAAP earnings — dividends declared per share $0.670 ÷ diluted EPS $1.78
- Operating cash flow — dividends paid $378m ÷ operating cash flow $2,490m
Where the figures came from
- 10-K filed 2026-02-11 · accession 0001802768-26-000003
All public at sec.gov — you should not have to take our word for it.
Caveats on this company
- DPS derived from dividends paid ($0.67); no per-share tag filed
Computed straight from SEC XBRL. A number that looks wrong to you is more useful to us than agreement — tell us.
What the operating cash flow payout ratio measures, and where every company here sits on it.
Also on: rated tight · when it files.
When this changes
Every figure above is recomputed whenever Royalty Pharma files. The monthly letter carries what filed, what moved, and one finding computed across every company here.